A quantitative promoter methylation profile of prostate cancer

被引:190
作者
Jerónimo, C
Henrique, R
Hoque, MO
Mambo, E
Ribeiro, FR
Varzim, G
Oliveira, J
Teixeira, MR
Lopes, C
Sidransky, D
机构
[1] Johns Hopkins Univ, Sch Med, Head & Neck Canc Res Div, Baltimore, MD 21205 USA
[2] Johns Hopkins Univ, Sch Med, Dept Otolaryngol Head & Neck Surg, Baltimore, MD 21205 USA
[3] Portuguese Oncol Inst Porto, Dept Genet, Oporto, Portugal
[4] Portuguese Oncol Inst Porto, Dept Pathol, Oporto, Portugal
[5] Portuguese Oncol Inst Porto, Dept Urol, Oporto, Portugal
关键词
D O I
10.1158/1078-0432.CCR-04-0894
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Promoter hypermethylation is an alternative pathway for gene silencing in neoplastic cells and a promising cancer detection marker. Although quantitative methylation-specific PCR (QMSP) of the GSTP1 promoter has demonstrated near perfect specificity for cancer detection in prostate biopsies, we postulated that identification and characterization of additional methylation markers might further improve its high (80-90%) sensitivity. Experimental Design: We surveyed nine gene promoters (GSTP1, MGMT, p14/ARF, p16/CDKN2A, RASSF1A, APC, TIMP3, S100A2, and CRBP1) by QMSP in tissue DNA from 118 prostate carcinomas, 38 paired high-grade prostatic intraepithelial neoplasias (HGPIN), and 30 benign prostatic hyperplasias (BPH). The methylation levels were calculated and were correlated with clinical and pathologic indicators. Results: Only the methylation frequencies of GSTP1 and APC were significantly higher in prostate carcinoma compared with BPH (P < 0.001). Methylation levels of GSTP1, APC, RASSF1A, and CRBP1, differed significantly between prostate carcinoma and HGPIN, and/or HGPIN or BPH (P < 0.0001). With QMSP and empirically defined cutoff values, the combined use of GSTP1 and APC demonstrated a theoretical sensitivity of 98.3% for prostate carcinoma, with 100% specificity. Methylation levels-were found to correlate with tumor grade (GSTP1 and APC) and stage (GSTP1, RASSF1A, and APC). Conclusions: Our data demonstrate the existence of a progressive increase of promoter methylation levels of several cancer-related genes in prostate carcinogenesis, providing additional markers to augment molecular detection of prostate carcinoma. Because methylation levels of GSTP1, APC, and RASSF1A are associated with advanced grade and stage, QMSP might augment the pathologic indicators currently used to predict tumor aggressiveness.
引用
收藏
页码:8472 / 8478
页数:7
相关论文
共 40 条
[1]   Molecular detection of tumor cells in bronchoalveolar lavage fluid from patients with early stage lung cancer [J].
Ahrendt, SA ;
Chow, JT ;
Xu, LH ;
Yang, SC ;
Eisenberger, CF ;
Esteller, M ;
Herman, JG ;
Wu, L ;
Decker, PA ;
Jen, J ;
Sidransky, D .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1999, 91 (04) :332-339
[2]  
Bostwick DG, 1996, EUR UROL, V30, P145
[3]  
Eads CA, 2001, CANCER RES, V61, P3410
[4]   Pathological and clinical characteristics of large prostate cancers predominantly located in the transition zone [J].
Erbersdobler, A ;
Huhle, S ;
Palisaar, J ;
Graefen, M ;
Hammerer, P ;
Noldus, J ;
Huland, H .
PROSTATE CANCER AND PROSTATIC DISEASES, 2002, 5 (04) :279-284
[5]   Tumour grade, proliferation, apoptosis, microvessel density, p53, and bcl-2 in prostate cancers:: Differences between tumours located in the transition zone and in the peripheral zone [J].
Erbersdobler, A ;
Fritz, H ;
Schnöger, S ;
Graefen, M ;
Hammerer, P ;
Huland, H ;
Henke, RP .
EUROPEAN UROLOGY, 2002, 41 (01) :40-46
[6]   CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future [J].
Esteller, M .
ONCOGENE, 2002, 21 (35) :5427-5440
[7]  
Esteller M, 2002, CANCER RES, V62, P5902
[8]   Cellular and molecular pathology of prostate cancer precursors [J].
Foster, CS ;
Bostwick, DG ;
Bonkhoff, H ;
Damber, JE ;
van der Kwast, T ;
Montironi, R ;
Sakr, WA .
SCANDINAVIAN JOURNAL OF UROLOGY AND NEPHROLOGY, 2000, 34 :19-43
[9]   PREDICTION OF PROGNOSIS FOR PROSTATIC ADENOCARCINOMA BY COMBINED HISTOLOGICAL GRADING AND CLINICAL STAGING [J].
GLEASON, DF ;
MELLINGE.GT .
JOURNAL OF UROLOGY, 1974, 111 (01) :58-64
[10]   Benign prostatic hyperplasia and prostate cancer [J].
Guess, HA .
EPIDEMIOLOGIC REVIEWS, 2001, 23 (01) :152-158